CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of severe diseases and conditions, today reported financial results for the second quarter ended June 30, 2016. Total net revenues for the quarter ended June 30, 2016 were approximately $12.8 million and included approximately […]